Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Cabometyx is Exelixis' lead drug. The settlement agreement resolves two patent litigations brought by Exelixis in response to Cipla's abbreviated new drug application (ANDA). The ANDA is seeking approval to market generic versions of Cabometyx tablets prior to the expiration of the applicable patents. The first case relates to Cipla's ANDA for a 60 mg cabozantinib dosage strength. This case was filed on Mar 16, 2023. The second case was filed on May 9, 2024, and relates to a recent amendment to Cipla's ANDA for the primary purpose of seeking additional approval for 20 mg and 40 mg cabozantinib dosage strengths. Per the settlement, Exelixis will grant Cipla a license to market generic versions of Cabometyx in the United States beginning on Jan 1, 2031, upon FDA approval and subject to conditions and exceptions common to agreements of this type. Both parties will terminate all ongoing Hatch-Waxman litigation between Exelixis and Cipla regarding Cabometyx patents pending in the
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis, Inc. (NASDAQ: EXEL) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Exelixis (EXEL) Down 6.6% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Exelixis to Present at the William Blair 44th Annual Growth Stock ConferenceBusiness Wire
- Exelixis reaches Cabometyx patent settlement with Cipla [Seeking Alpha]Seeking Alpha
- Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 4/30/24 - Miss
EXEL
Sec Filings
- 6/6/24 - Form 4
- 6/4/24 - Form 4
- 6/4/24 - Form 4
- EXEL's page on the SEC website